Definitive Healthcare posts Q1 2026 revenue of $55.9M, takes $197.2M goodwill impairment

Definitive Healthcare (Nasdaq: DH) reported Q1 2026 revenue of USD 55.9 million, down 6% year-over-year, and a net loss of USD 192.4 million driven almost entirely by a USD 197.2 million goodwill impairment charge.

The healthcare commercial-intelligence vendor flagged its Monocl expert-intelligence product as a strategic bright spot in an otherwise contracting quarter. According to the Q1 release, an existing Monocl customer expanded its commitment after being acquired by a larger biopharma organization, which DH framed as an upsell template for the post-M&A integration cycle.

What the numbers say

A USD 197.2 million goodwill impairment on a quarter where revenue came in at USD 55.9 million is, in plain terms, the company telling its auditors that prior acquisitions are worth materially less than what sits on the balance sheet. Impairments are non-cash, but they're rarely cosmetic. They mark a reset of management's own expectations for the acquired assets' future cash flows.

The 6% YoY revenue contraction is the more immediate operating signal. DH's core business sells healthcare commercial intelligence (hospital data, physician data, claims-linked datasets) into life sciences, providers, and staffing firms. Top-line shrinkage in a category that competitors like IQVIA and Veeva treat as foundational suggests either pricing pressure, net revenue retention slipping below 100%, or both.

The Monocl angle

Monocl, which DH acquired in 2020, is the company's KOL-mapping and expert-intelligence layer. It identifies and profiles healthcare key opinion leaders for life-sciences commercial and medical-affairs teams. Functionally, it's adjacent to the expert-network category, though the workflow is closer to relationship mapping than paid expert calls.

DH's call-out matters for two reasons. First, it positions Monocl as the part of the portfolio that's still expanding inside accounts. Second, it implicitly concedes that the broader DH dataset isn't carrying the same upsell momentum.

The customer-expansion story DH described, an existing Monocl user that was acquired by a larger pharma and then expanded the contract, is the kind of motion expert-intelligence vendors want to industrialize. Post-acquisition, the acquirer typically rationalizes vendor sprawl. If your product survives that review and gets a bigger footprint, it's stickier than the category average.

Three reads on the quarter

Bear case: The impairment confirms that DH overpaid for prior acquisitions and the core data business is in structural decline. Revenue falls again in Q2. Operating leverage doesn't return until the cost base is rebuilt around a smaller revenue envelope.

Base case: The impairment is a clean-up quarter. Revenue stabilizes in the second half as Monocl-shaped expansions and a leaner cost structure offset churn in the legacy data business. The company trades on Monocl growth and free cash flow rather than top-line acceleration.

Bull case: Monocl is mispriced inside DH. If expert-intelligence revenue is growing inside an otherwise flat composite, the segment-level story is better than the consolidated print. A more aggressive disclosure split, or a strategic carve-out, would reset how the market values the asset.

Q2 guidance was issued with the release. The line to watch on the next call is whether Monocl gets a standalone growth-rate disclosure, which would be the cleanest signal that management thinks the segment story can carry the stock.